Navigation path

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia


   Infocentre

Published: 4 December 2015  
Related theme(s) and subtheme(s)
Health & life sciencesMedical research
Countries involved in the project described in the article
Brazil  |  France  |  Germany  |  Greece  |  Hungary  |  Italy
Add to PDF "basket"

EU-Brazil partnership signals new era for anti-inflammatory therapies

Through close cooperation between European and Brazilian scientists, an EU-funded project is developing and currently testing novel preclinical drug candidates designed to prevent various chronic autoimmune and inflammatory diseases.

Photo of patient holding pill and glass of water

© thodonal - Fotolia.com

The TARKINAID project is in the process of validating the use of these newly developed anti-inflammatory agents, which inhibit a particular family of signalling molecules. If successful, the team hopes to be able to develop entirely novel small-molecule inhibitors as oral anti-inflammatory therapeutics.

Besides its scientific achievements, the project also brought together scientists from various countries, encouraging the development of a network between European and Brazilian immunologists (two group leaders are from Brazil) and promoting research in Eastern European countries (the coordinator and one SME partner are from Hungary).

Addressing a chronic problem

Autoimmune diseases occur when the immune system mistakes its own tissue as foreign and mounts an attack. The overproduction of certain signalling molecules – produced by cells to carry out specific biological functions – can lead to chronic autoimmune and inflammatory diseases such as rheumatoid arthritis or chronic inflammatory lung diseases. These debilitating conditions can strongly impair quality of life.

“Chronic inflammatory diseases are also a major burden to society, which is why the development of novel therapeutic strategies is a research priority,” says project coordinator Attila Mócsai, Professor at the Semmelweis University School of Medicine in Budapest, Hungary. “However, therapeutic options are still limited, in part because of side effects and very high costs, and because of our limited understanding of the pathological mechanisms involved.”

Testing targeted therapies

This was the motivation for the TARKINAID project. Prior to the start of the project in January 2012, members of the consortium had demonstrated that certain signalling molecules – called Src-family tyrosine kinases – play an important role in certain types of tissue inflammation. “Src-family kinases have recently emerged as major therapeutic targets in malignant diseases, but their suitability as potential targets of inflammatory diseases has not yet received widespread acceptance,” says Mócsai.

Building on this knowledge, three key objectives for the TARKINAID project were identified: to develop novel Src-family kinase inhibitors that effectively address chronic autoimmune and inflammatory diseases; to analyse the effect of known Src-family inhibitors already in use; and to analyse the effect of genetics on inflammation susceptibility. A core part of the TARKINAID project has been pre-clinical analysis of novel Src-family kinase inhibitors in mice, supported by in vitro and in vivo experiments to predict and optimise the most promising inhibitors and to test their safety.

So far, the team has developed and tested a number of novel Src-family inhibitors, which have had a major effect on inflammatory cell function. “We have also identified a number of unexpected effects of an anti-cancer drug on inflammatory cell function, and revealed that having a genetic deficiency of Src-family kinases can cancel out inflammatory processes in mice,” says Mócsai. “Members of the consortium have also obtained genetic evidence showing that Src-family kinases play a key role in autoimmune inflammatory diseases such as rheumatoid arthritis or blistering skin diseases.”

Src-family kinases could hold the key to more effective treatments of chronic immune and inflammatory diseases in the future. Results of the project to date have been presented at various international meetings and in a number of scientific publications.

Project details

  • Project acronym: TARKINAID
  • Participants: Hungary (Coordinator), France, Germany, Italy, Brazil, Greece
  • Project reference: 282095
  • Total cost: € 3 912 000
  • EU contribution: € 2 999 860
  • Duration: January 2012 - December 2015

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project Website
Project details






  Top   Research Information Center
 
Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  Gambia
  Georgia